Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jun;23(6):e13435.
doi: 10.1111/obr.13435. Epub 2022 Feb 22.

Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials

Junaid Iqbal  1 , Hui-Xuan Wu  1 , Nan Hu  1 , Ying-Hui Zhou  1 , Long Li  1 , Fen Xiao  1 , Ting Wang  1 , Hong-Li Jiang  1 , Shi-Na Xu  1 , Bi-Ling Huang  1 , Hou-De Zhou  1
Affiliations
Meta-Analysis

Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials

Junaid Iqbal et al. Obes Rev. 2022 Jun.

Abstract

Clinical trials have investigated the weight loss effect of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in adults with obesity without diabetes mellitus, but results for weight loss efficacy were varied. We aimed to provide an up-to-date systematic review and meta-analysis for overall weight loss effect of GLP-1 RA in adults with obesity and overweight without diabetes mellitus. We retrieved eligible randomized control trials that assessed the weight loss effect of GLP-1 RA in adults (≥18 years old) without type 1/type 2 diabetes up to September 30, 2021, using Pubmed and Embase. Of 36 clinical trials assessed for eligibility, 12 trials were included, with a combined total of 11,459 participants. Compared with control groups, a more significant weight loss was seen in GLP-1 RA groups with an overall mean difference of -7.1 kg (95% CI -9.2 to -5.0) (I2 = 99%). The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events. Better control of blood pressure and plasma levels of LDL, HDL, and triglycerides was seen with GLP-1 RA treatment. Subgroup analysis showed greater treatment effect of semaglutide than liraglutide. Vomiting, nausea, dyspepsia, diarrhea, constipation, and abdominal pain were GLP-1 RA-associated common adverse effects.

Keywords: diabetes mellitus; glucagon-like peptide; obesity; weight loss.

PubMed Disclaimer

References

REFERENCES

    1. World Health Organization. Obesity and Overweight 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
    1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. doi:10.1186/1471-2458-9-88
    1. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344(jan10 2):d7771. doi:10.1136/bmj.d7771
    1. Norris SL, Zhang X, Avenell A, Gregg E, Brown T, Schmid CH, Lau J, Cochrane Metabolic and Endocrine Disorders Group. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev 2005;2005(2):Cd004095. doi:10.1002/14651858.CD004095.pub2
    1. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J am Diet Assoc. 2007;107(10):1755-1767. doi:10.1016/j.jada.2007.07.017

Publication types

Substances

LinkOut - more resources